Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
Gut and Liver
; : 201-207, 2018.
Article
em En
| WPRIM
| ID: wpr-713230
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND/AIMS:
Changes in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated.METHODS:
Dynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV).RESULTS:
Total, LDL−, and HDL-cholesterol levels increased rapidly and persistently after week 4. Apolipoprotein (apo) A-I, apo B, apo C-II, and apo C-III levels were significantly higher at week 4 than at week 0. In contrast, apo A-II and apo E levels were significantly lower. The differences in LDL− and HDL-cholesterol levels were positively correlated with those of apo B and apo A-I, respectively. Interestingly, in patients with non-sustained virological response, these cholesterol levels decreased rapidly after viral breakthrough or viral relapse. Furthermore, similar changes were observed for apo A-I, apo B and apo C-III levels.CONCLUSIONS:
Clearance of HCV using combination therapy with DCV and ASV results in rapid changes in serum lipid profiles, suggesting an influence of HCV infection on disturbed lipid metabolism.Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Apolipoproteínas
/
Apolipoproteínas B
/
Apolipoproteínas E
/
Recidiva
/
Colesterol
/
Apolipoproteína A-II
/
Apolipoproteína A-I
/
Hepatite C
/
Hepacivirus
/
Metabolismo dos Lipídeos
Limite:
Humans
Idioma:
En
Revista:
Gut and Liver
Ano de publicação:
2018
Tipo de documento:
Article